Quest Diagnostics Inc. (DGX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Quest Diagnostics’s revenue went from $7.2B in fiscal 2016 to $11.0B in fiscal 2025, growth of about 4.8% a year.
Net income in fiscal 2025 was $992M, a net margin of 9.0%; the best year in this period was 2021 with $2.0B.
Over the twelve months to September 30, 2026, revenue was $11.8B and net income $1.1B.
Free cash flow was $1.4B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 20% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8B | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B | $9.4B | $7.7B | $7.5B | $7.4B | $7.2B |
| Gross profit | $3.9B | $3.7B | $3.2B | $3.1B | $3.4B | $4.2B | $3.6B | $2.7B | $2.6B | $2.7B | $2.9B |
| Operating income | $1.7B | $1.6B | $1.3B | $1.3B | $1.4B | $2.4B | $2.0B | $1.2B | $1.1B | $1.2B | $1.3B |
| Net income | $1.1B | $992M | $871M | $854M | $946M | $2.0B | $1.4B | $858M | $736M | $772M | $645M |
| EPS (diluted) | $10.04 | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +11.8% | +6.7% | −6.4% | −8.4% | +14.3% | +22.1% | +2.6% | +1.7% | +2.6% | −3.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.0B | $1.9B | $1.3B | $1.3B | $1.7B | $2.2B | $2.0B | $1.2B | $1.2B | $1.2B | $1.1B |
| Capital spending | -$576M | -$527M | -$425M | -$408M | -$404M | -$403M | -$418M | -$400M | -$383M | -$252M | -$293M |
| Free cash flow | $1.4B | $1.4B | $909M | $864M | $1.3B | $1.8B | $1.6B | $843M | $817M | $923M | $823M |
| Dividends paid | $369M | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M |
| Buybacks | $552M | $450M | $151M | $275M | $1.4B | $2.2B | $325M | $353M | $322M | $465M | $590M |
| Stock-based pay | $88M | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $420M | $549M | $686M | $315M | $872M | $1.2B | $1.2B | $135M | $137M | $359M |
| Debt | — | $6.4B | $6.9B | $5.4B | $4.6B | $4.7B | $4.7B | $5.3B | $4.4B | $3.8B | $3.7B |
| Equity | — | $7.2B | $6.8B | $6.3B | $5.9B | $6.4B | $6.8B | $5.6B | $5.2B | $4.9B | $4.6B |
| Total assets | — | $16.2B | $16.2B | $14.0B | $12.8B | $13.6B | $14.0B | $12.8B | $11.0B | $10.5B | $10.1B |
| Shares (diluted) | 112M | 113M | 113M | 113M | 118M | 128M | 136M | 136M | 139M | 140M | 142M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 33.1% | 33.2% | 32.9% | 33.0% | 34.7% | 39.0% | 38.5% | 34.8% | 34.6% | 36.2% | 40.2% |
| Operating margin | 14.6% | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.7% | 17.7% |
| Net margin | 9.5% | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.4% | 8.9% |
| FCF margin | 11.6% | 12.3% | 9.2% | 9.3% | 13.3% | 17.0% | 16.8% | 10.9% | 10.8% | 12.5% | 11.4% |
| ROIC | — | 8.8% | 7.5% | 8.4% | 10.7% | 16.5% | 13.1% | 8.6% | 9.2% | 10.2% | 9.2% |
| ROE | — | 13.8% | 12.8% | 13.5% | 16.1% | 31.0% | 21.2% | 15.2% | 14.1% | 15.7% | 13.9% |
Frequently asked questions
What is Quest Diagnostics’s annual revenue?
$11.0B in fiscal 2025 and $11.8B over the twelve months to September 30, 2026.
How much profit does Quest Diagnostics make?
Net income was $992M in fiscal 2025 (net margin 9.0%).
Is Quest Diagnostics’s revenue growing?
Yes: revenue rose 11.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.